Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia.

Miyamoto S, Wolfgang Fleischhacker W.

Curr Treat Options Psychiatry. 2017;4(2):117-126. doi: 10.1007/s40501-017-0115-z. Epub 2017 Apr 19. Review.

2.

Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone.

Ivaturi V, Gopalakrishnan M, Gobburu JVS, Zhang W, Liu Y, Heidbreder C, Laffont CM.

Br J Clin Pharmacol. 2017 Jul;83(7):1476-1498. doi: 10.1111/bcp.13246. Epub 2017 Mar 31.

PMID:
28133766
3.

Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability.

Singh SM, Haddad PM, Husain N, Heaney E, Tomenson B, Chaudhry IB.

Ther Adv Psychopharmacol. 2016 Jun;6(3):162-71. doi: 10.1177/2045125316632458. Epub 2016 Mar 10.

4.

Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study.

Peters-Strickland T, Baker RA, McQuade RD, Jin N, Eramo A, Perry P, Johnson BR, Duca A, Sanchez R.

NPJ Schizophr. 2015 Nov 4;1:15039. doi: 10.1038/npjschz.2015.39. eCollection 2015.

5.

Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.

Fu DJ, Turkoz I, Simonson RB, Walling D, Schooler N, Lindenmayer JP, Canuso C, Alphs L.

J Clin Psychopharmacol. 2016 Aug;36(4):372-6. doi: 10.1097/JCP.0000000000000535.

7.

Five-year patient outcomes with risperidone long-acting injection or oral aripiprazole.

Deslandes PN, Dwivedi M, Sewell RD.

Ther Adv Psychopharmacol. 2015 Jun;5(3):151-7. doi: 10.1177/2045125315581997.

8.

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study.

Si T, Zhang K, Tang J, Fang M, Li K, Zhuo J, Feng Y.

Neuropsychiatr Dis Treat. 2015 Jun 22;11:1483-92. doi: 10.2147/NDT.S81760. eCollection 2015.

9.

The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V.

Ther Adv Psychopharmacol. 2014 Oct;4(5):198-219. doi: 10.1177/2045125314540297. Review.

10.

Placebo response in antipsychotic clinical trials: a meta-analysis.

Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA.

JAMA Psychiatry. 2014 Dec 1;71(12):1409-21. doi: 10.1001/jamapsychiatry.2014.1319. Erratum in: JAMA Psychiatry. 2015 Jan;72(1):96.

11.

Psychotic disorders in children and adolescents: a primer on contemporary evaluation and management.

Stevens JR, Prince JB, Prager LM, Stern TA.

Prim Care Companion CNS Disord. 2014;16(2). pii: PCC.13f01514. doi: 10.4088/PCC.13f01514. Epub 2014 Mar 13. No abstract available.

12.

Risperidone long-acting injection in the treatment of schizophrenia spectrum illnesses: A retrospective chart review of 19 patients in the Vancouver Community Mental Health Organization (Vancouver, Canada).

Ganesan S, McKenna M, Procyshyn RM, Zipursky S.

Curr Ther Res Clin Exp. 2007 Nov;68(6):409-20. doi: 10.1016/j.curtheres.2007.12.002. Erratum in: Curr Ther Res Clin Exp. 2008 Feb;69(1):101.

13.

Development of Risperidone PLGA Microspheres.

D'Souza S, Faraj JA, Giovagnoli S, Deluca PP.

J Drug Deliv. 2014;2014:620464. doi: 10.1155/2014/620464. Epub 2014 Jan 28.

14.

Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada.

Williams R, Chandrasena R, Beauclair L, Luong D, Lam A.

Neuropsychiatr Dis Treat. 2014 Feb 27;10:417-25. doi: 10.2147/NDT.S54740. eCollection 2014.

15.

Six-month open-label follow-up of risperidone long-acting injection use in pediatric bipolar disorder.

Boarati MA, Wang YP, Ferreira-Maia AP, Cavalcanti AR, Fu-I L.

Prim Care Companion CNS Disord. 2013;15(3). pii: PCC.12m01368. doi: 10.4088/PCC.12m01368. Epub 2013 May 2.

16.

Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis.

Kirschner M, Theodoridou A, Fusar-Poli P, Kaiser S, Jäger M.

Ther Adv Psychopharmacol. 2013 Apr;3(2):89-99. doi: 10.1177/2045125312464106.

17.

A study of the efficacy and safety of switching from oral risperidone to risperidone long-acting injection in older patients with schizophrenia.

Suzuki H, Inoue Y, Gen K.

Ther Adv Psychopharmacol. 2012 Dec;2(6):227-34. doi: 10.1177/2045125312457585.

18.

Risperidone long-acting injection: safety and efficacy in elderly patients with schizophrenia.

Catalán R, Penadés R.

J Cent Nerv Syst Dis. 2011 May 18;3:95-105. doi: 10.4137/JCNSD.S4125. Print 2011.

19.
20.

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics.

Alphs L, Bossie CA, Sliwa JK, Fu DJ, Ma YW, Hulihan J.

Neuropsychiatr Dis Treat. 2013;9:341-50. doi: 10.2147/NDT.S36438. Epub 2013 Mar 5.

Supplemental Content

Support Center